Background: Distinguishing alveolar rhabdomyosarcoma (ARMS) from embryonal rhabdomyosarcoma (ERMS) has historically been of prognostic and therapeutic importance. However, classification has been complicated by shifting histologic criteria required for an ARMS diagnosis. Children's Oncology Group (COG) studies after IRS-IV, which included the height of this diagnostic shift, showed both an increased number of ARMS and an increase in the proportion of fusion-negative ARMS. Following diagnostic standardization and histologic re-review of ARMS cases enrolled during this era, analysis of low-risk (D9602) and intermediate-risk (D9803) rhabdomyosarcoma (RMS) studies showed that fusion status rather than histology best predicts prognosis for patients with RMS. This analysis remains to be completed for patients with high-risk
INTRODUCTION
Between 1995 and 2005, there was a shift in the histologic criteria required for a diagnosis of alveolar rhabdomyosarcoma (ARMS).
This shift followed publication of the International Classification of Rhabdomyosarcoma (ICR), which was the first prognostically relevant classification system for rhabdomyosarcoma (RMS). 1 The ICR identified three prognostic groups: botryoid and spindle cell RMS had a superior prognosis, conventional embryonal rhabdomyosarcoma (ERMS) had an intermediate prognosis, and ARMS had a poor prognosis. However, the ICR also broadened the diagnostic criteria for ARMS to include the solid variant and tumors with only focal alveolar histology, when previously a diagnosis of ARMS required >50% classic alveolar histology. This change increased both the frequency of ARMS diagnoses and the proportion of FOXO1 fusion-negative ARMS. [2] [3] [4] Studies have examined the effect of this histologic shift in patients with low-risk clinical characteristics enrolled on Children's Oncology Group (COG) Study D9602, as well as in patients with intermediaterisk RMS enrolled on COG Study D9803. [4] [5] [6] Fifty-two percent of cases originally enrolled on D9602 with a diagnosis of ARMS were reclassified as ERMS, whereas 33% of cases enrolled on D9803 were similarly reclassified. Upon re-review using current diagnostic criteria, the percentage of ARMSn on D9803 decreased from 37 to 18% of total ARMS diagnoses, a ratio more closely approaching earlier reports. 4 These reviews validated the current criteria for ARMS, standardized the diagnosis of ARMS across COG studies, and allowed definitive analysis of the prognostic significance of histology and fusion status for patients with RMS. As predicted by retrospective gene expression studies showing that ARMSn and ERMS are molecularly indistinguishable, analysis of these prospective studies confirmed that the presence of a PAX-FOXO1 fusion drives unfavorable outcome for children with RMS. [5] [6] [7] [8] Based on these data, we hypothesized that (1) a significant number of high-risk, metastatic ARMS would be reclassified as other histologic subtypes and (2) fusion status would have similar prognostic significance for these high-risk patients. 
MATERIALS AND METHODS

Case selection
Histology review
Four pathologists (ERR, MAA, LAT, and DMP) participated in the rereview. Cases were re-classified as ARMS (solid or classic patterns), ERMS (typical, dense or botryoid), spindle cell/sclerosing RMS, mixed RMS (defined as separate, discrete areas of ARMS and ERMS histology), or RMS not otherwise specified (NOS) if the material was too small, crushed, or necrotic for definitive histologic classification. 4 In cases difficult to classify, diffuse myogenin reactivity favored a diagnosis of ARMS over ERMS. Myogenin immunohistochemistry was available for 60 D9802 cases and 58 ARST0431 cases. Nuclear myogenin expression was scored from 0 to 4+ based on the following percentages of tumor cells: 0 (absent expression), 1+ (<10%), 2+ (10-50%), 3+ (>50-90%), and 4+ (>90%). 11 The histologic type was determined prior to FOXO1 fusion status testing.
TA B L E 1 D9802 and ARST0431 cases included in outcome analysis
Fusion testing
In most cases (81 of 85), fusion status was determined by FISH to detect rearrangements of the FOXO1 (13q14), PAX3 (2q35), and PAX7 (1p36) loci using unstained formalin-fixed, paraffin-embedded tissue sections, as previously described. 12 In the other four cases, fusion status was previously determined by quantitative reverse transcription PCR to detect expression of a PAX3-FOXO1 or PAX7-FOXO1 fusion transcript, as previously described. 13 Fusion testing was not performed in the remaining cases due to a lack of available material.
Patient characteristics and statistical analyses
Event-free survival (EFS) was defined as the time from study entry to the first occurrence of disease progression, disease relapse, or death.
For those not experiencing one of these events, EFS was censored at last contact. Estimates of overall survival (OS) and EFS as time-to-event distributions were calculated using the Kaplan-Meier method, and distributions were compared using log-rank tests.
Clinical characteristics were reviewed to generate an overall risk score based on the factors presented by Oberlin et al. 14 Using this scheme, four risk factors (age <1 or ≥10 years, presence of bone or bone marrow disease, unfavorable primary site and ≥3 metastatic sites) were each assigned 1 point. Patients with a score of 0 or 1 were considered low risk, while scores ≥2 were considered high risk. The EFS was compared between fusion statuses, after stratification by risk category.
RESULTS
Histologic Re-review
Histology re-review was performed for 86 RMS cases enrolled on D9802, although four were later deemed ineligible for the final outcome analysis ( Supplementary Fig. S1A ). For cases with an original central pathology diagnosis of ARMS (n = 73), the diagnosis was confirmed in 58 cases (79%). Nine cases were reclassified as ERMS (12%), one was reclassified as mixed RMS (1%), and five were reclassified as RMS NOS due to lack of sufficient material. 
Fusion status
Fusion status was determined for 63% of confirmed ARMS cases (29 enrolled on D9802 and 51 enrolled on ARST0431), but material was not available for fusion testing in the remaining cases (Table 2 ).
Five cases reclassified as ERMS also had material available for fusion testing. One D9802 case reclassified as RMS NOS was fusion negative, while fusion status was unknown for the remaining four cases; one ARST0431 case reclassified as RMS NOS was fusion positive, while fusion status was unknown for the other case. RMS NOS cases were excluded from the final outcome analyses, however (Supplementary Fig. S1B ). Fusion status was unknown for all other remaining cases, including 48 confirmed ARMS (31 from D9802 and 17 from ARST0431). For either study, ERMS cases lacking fusion data were considered to be fusion negative.
Twelve (15%) of the confirmed ARMS cases with available fusion data were fusion negative (five from D9802 and seven from ARST0431), whereas 68 (85%) of confirmed ARMS cases with known fusion status were fusion positive ( 
Clinical features
Clinical characteristics for the 178 patients included in the outcome analysis showed a predominance of male patients (52%, n = 94), age ≥ 10 years (70%, n = 125), with bone or bone marrow disease (52%, n = 94). Primary tumor sites included extremity (26%, n = 46), retroperitoneum/perineum (24%, n = 42), parameningeal (11%, n = 19), trunk (10%, n = 18), genitourinary, nonbladder/prostate (10%, n = 18), bladder/prostate (5%, n = 10), intrathoracic (4%, n = 7), head and neck (3%, n = 5), and other (7%, n = 13) (Supplementary Table S1 ).
TA B L E 3
Using the Oberlin risk groups, 14 
Outcome
Five-year EFS for the entire cohort (n = 178) was 22% (95% confidence interval [CI]: 16-29%). There was a difference in EFS by study: 5-year EFS for D9802 and ARST0431 was 15% (95% CI 8-23%) and 30% (95% CI 20-40%), respectively (P = 0.0014) (Fig. 1A) . The difference in EFS was restricted to patients with ERMS: 5-year EFS was 23% for D9802
(95% CI 8-41%) compared to 59% for ARST0431 (95% CI 39-75%) (P = 0.012), which is accounted for by the exclusion of patients less than 10 years of age with metastatic ERMS on D9802 (Fig. 1B) . There was no significant difference in 5-year EFS for patients with ARMS:
D9802, 12% (95% CI 5-21%) versus ARST0431, 16% (95% CI 8-27%) (P = 0.057) (Fig. 1C) .
When analyzed by histology and fusion status, the 5-year EFS between all histologic subsets were as follows: ERMS = 43% (95% CI 29-56%), fusion negative ARMS = 29% (95% CI 7-56%), ARMSunknown = 17% (95% CI 8-30%), ARMS-PAX7 = 17% (95% CI 1-51%), and ARMS-PAX3 = 8% (95% CI 3-17%) (P = 0.020) ( Fig. 2A) . No statistically significant differences in OS were seen among these subsets (P = 0.14). Additionally, although there was a quantitative difference in EFS between fusion negative and fusion positive cases with exclusively alveolar histology (including both PAX3 and PAX7-FOXO1 (n = 62) of 40% (95% CI 28-52%) (P = 0.0012) (Fig. 2B) . OS for RMSp was approximately 20% versus 50% for RMSn (P = 0.029). 18.2%); and Oberlin 4, 0% (P < 0.0001) (Fig. 3) . Factoring in fusion status has no significant effects on the 5-year EFS when stratified by Oberlin score (Table 3) . For patients with a low-risk score (Oberlin 0 or 1), there was a trend toward inferior outcome for RMSp as compared to RMSn; however, overall the Oberlin score remained predictive independent of fusion status for patients with metastatic RMS.
Previous studies have addressed histology and fusion status in lowand intermediate-risk RMS. [4] [5] [6] This study provides the first analysis for high-risk RMS enrolled in two consecutive COG studies using cur- Potential weaknesses of the study include the availability of fusion data for only 65% of ARMS enrolled on the study, which could lead to erroneous conclusions when evaluating a "convenience cohort." 16 There were few fusion negative ARMS cases, and a larger analysis is needed. Additionally, fusion data for patients with metastatic ERMS were not available for many cases; however, fusion-positive ERMS is very rare. 3, 5 The superior outcome for patients with metastatic ERMS also provides support that fusionpositive ERMS is exceedingly rare for high-risk patients as well. Future studies will include analysis of FOXO1 fusion status for all histologic subtypes of RMS, allowing a more rigorous examination of this group.
This study resolves the variation in histologic classification for a generation of COG RMS studies, providing standardized diagnoses for all patients with ARMS enrolled during that era by current histologic criteria. Additionally, our data demonstrate that FOXO1 fusion status is associated with a higher Oberlin score for patients with metastatic RMS, but the these clinical risk factors remain the most predictive marker of poor outcome for patients with metastatic RMS. This study provides the foundation for future analysis of risk stratification with the addition of molecular data across all risk groups, including recent generations of COG studies.
